Study of graft fibrosis after pediatric living donor liver transplantation for biliary atresia in association with humoral rejection
| Project/Area Number |
25861667
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Pediatric surgery
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 小児 / 肝移植 / 線維化 / 液性免疫 / ドナー特異的抗体 / グラフト / 液性拒絶 |
|---|
| Outline of Final Research Achievements |
Pediatric living donor liver transplant (LDLT) patients sometimes develops graft fibrosis. Therefore, we have performed serial protocol biopsies. They showed graft fibrosis even if their liver function tests were within normal range. Recently donor specific antibody (DSA) may have a role in graft damage after liver transplantation. We investigated rate of graft fibrosis in pediatric patients after LDLT and the mechanism of fibrosis focusing the DSA.
Twenty three patients who were received the liver during childhood due to biliary atresia enrolled in this study. Graft fibrosis was observed in 17 patients (74%). Positive DSA patients tend to develop graft fibrosis. Further follow up is required to determine the relationship between fibrosis progression and DSA; however, our findings are expected to lead long term alive of pediatric patients after LDLT preventing graft fibrosis.
|
Report
(4 results)
Research Products
(2 results)
